Immuneering Corp (IMRX) — SEC Filings
Immuneering Corp (IMRX) — 33 SEC filings. Latest: 10-Q (Nov 12, 2025). Includes 12 8-K, 9 SC 13G/A, 6 10-Q.
View Immuneering Corp on SEC EDGAR
Overview
Immuneering Corp (IMRX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 12, 2025: Immuneering Corp (IMRX) reported a net loss of $14,964,875 for the three months ended September 30, 2025, an increase from $14,597,366 for the same period in 2024. For the nine months ended September 30, 2025, the net loss widened to $44,444,888 from $42,985,123 in the prior year. Research and devel
Sentiment Summary
Across 33 filings, the sentiment breakdown is: 4 bullish, 1 bearish, 27 neutral, 1 mixed. The dominant filing sentiment for Immuneering Corp is neutral.
Filing Type Overview
Immuneering Corp (IMRX) has filed 6 10-Q, 12 8-K, 2 DEF 14A, 2 10-K, 9 SC 13G/A, 1 8-K/A, 1 SC 13G with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (33)
Risk Profile
Risk Assessment: Of IMRX's 21 recent filings, 2 were flagged as high-risk, 12 as medium-risk, and 7 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$14,964,875 |
| EPS | -$0.38 |
| Debt-to-Equity | 0.06 |
| Cash Position | $227,563,077 |
| Operating Margin | N/A |
| Total Assets | $241,056,266 |
| Total Debt | $13,079,834 |
Key Executives
- Dr. Sarah E. Bloch
- Ms. Jennifer L. Jones
- Robert J. Carpenter
- Benjamin J. Zeskind, Ph.D.
- Dr. Sarah Hough
- Dr. David L. Brown
Industry Context
Immuneering Corp operates in the biotechnology sector, a highly competitive and capital-intensive industry focused on drug discovery and development. Companies in this space typically incur substantial R&D expenses for extended periods before achieving profitability, often relying on significant external funding through equity offerings and strategic partnerships. The success of such companies is heavily dependent on clinical trial outcomes and regulatory approvals.
Top Tags
acquisition (4) · 10-Q (4) · SEC Filing (3) · merger (3) · corporate-governance (3) · financials (3) · Biotechnology (2) · Oncology (2) · Clinical Stage (2) · material-definitive-agreement (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Cash and cash equivalents | $227,563,077 | Increased from $36,144,720 at December 31, 2024, a 529% increase, significantly extending cash runway. |
| Net loss for Q3 2025 | $14,964,875 | Increased from $14,597,366 in Q3 2024, indicating continued operational losses. |
| Net loss for nine months ended Sept 30, 2025 | $44,444,888 | Widened from $42,985,123 in the prior year, reflecting ongoing R&D investments. |
| Accumulated deficit | $268,740,074 | As of September 30, 2025, highlighting the company's pre-revenue stage and historical losses. |
| Proceeds from public offering | $164,086,975 | Net proceeds from a public offering, a major contributor to the increased cash balance. |
| Proceeds from private placement with Aventis Inc. | $23,300,000 | Net proceeds from a strategic private placement, further strengthening the balance sheet. |
| Class A common stock shares outstanding | 63,483,397 | As of September 30, 2025, up from 31,050,448 at December 31, 2024, indicating significant shareholder dilution from capital raises. |
| Research and development expenses for nine months ended Sept 30, 2025 | $32,793,835 | Slightly decreased from $33,107,222 in the prior year, but remains the largest operating expense. |
| Net loss for six months | $29.48M | Widened from $28.39M in the prior year, showing increasing operational losses. |
| Proceeds from at-the-market offering | $13.68M | Capital raised to partially offset cash burn, indicating reliance on equity financing. |
| Total assets | $40.06M | Decreased from $52.71M at Dec 31, 2024, reflecting asset depletion. |
| Net loss for three months | $14.43M | Increased from $14.08M in Q2 2024, showing continued quarterly losses. |
| Research and development expenses for six months | $21.93M | Consistent with $21.85M in prior year, indicating sustained R&D investment. |
| Net loss per share (diluted) for six months | $0.82 | Compared to $0.96 in prior year, showing some per-share improvement despite higher net loss due to increased share count. |
| Acquisition Value | $625M | Total cash consideration for Immuneering Corp. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Immuneering Corp (IMRX)?
Immuneering Corp has 33 recent SEC filings from Jan 2024 to Nov 2025, including 12 8-K, 9 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of IMRX filings?
Across 33 filings, the sentiment breakdown is: 4 bullish, 1 bearish, 27 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Immuneering Corp SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Immuneering Corp (IMRX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Immuneering Corp?
Key financial highlights from Immuneering Corp's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for IMRX?
The investment thesis for IMRX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Immuneering Corp?
Key executives identified across Immuneering Corp's filings include Dr. Sarah E. Bloch, Ms. Jennifer L. Jones, Robert J. Carpenter, Benjamin J. Zeskind, Ph.D., Dr. Sarah Hough and 1 others.
What are the main risk factors for Immuneering Corp stock?
Of IMRX's 21 assessed filings, 2 were flagged high-risk, 12 medium-risk, and 7 low-risk.
What are recent predictions and forward guidance from Immuneering Corp?
Forward guidance and predictions for Immuneering Corp are extracted from SEC filings as they are enriched.